Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Workman

Showing results (161-170 of 315) with videos related to

Pageof 32
Sort By:
Cancer Research|January 11, 2007
Role for amplification and expression of glypican-5 in rhabdomyosarcomaDaniel Williamson, Joanna Selfe, Tony Gordon, et al.
Plos One|April 24, 2012
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageShane Zaidi, Martin McLaughlin, Shreerang A Bhide, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human gliomaSandrine Guillard, Paul A Clarke, Robert Te Poele, et al.
Molecular Cancer Therapeutics|May 30, 2006
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKTNivedita Sain, Bhavani Krishnan, Michael G Ormerod, et al.
Plos One|July 10, 2020
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSheelagh Frame, Chiara Saladino, Craig MacKay, et al.
The Biochemical Journal|August 15, 2019
Structural and functional characterisation of human RNA helicase DHX8 provides insights into the mechanism of RNA-stimulated ADP releaseCatarina Felisberto-Rodrigues, Jemima C Thomas, Craig McAndrew, et al.
Cancer Research|October 30, 2003
Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profilingPaul A Clarke, Mark L George, Sandra Easdale, et al.
Molecular Cancer Therapeutics|October 22, 2016
The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma CellsTeresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug developmentDaniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Pageof 32

Showing results (161-170 of 315) with videos related to

Sort By:
Pageof 32
Cancer Research|January 11, 2007
Role for amplification and expression of glypican-5 in rhabdomyosarcomaDaniel Williamson, Joanna Selfe, Tony Gordon, et al.
Plos One|April 24, 2012
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageShane Zaidi, Martin McLaughlin, Shreerang A Bhide, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human gliomaSandrine Guillard, Paul A Clarke, Robert Te Poele, et al.
Molecular Cancer Therapeutics|May 30, 2006
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKTNivedita Sain, Bhavani Krishnan, Michael G Ormerod, et al.
Plos One|July 10, 2020
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancerSheelagh Frame, Chiara Saladino, Craig MacKay, et al.
The Biochemical Journal|August 15, 2019
Structural and functional characterisation of human RNA helicase DHX8 provides insights into the mechanism of RNA-stimulated ADP releaseCatarina Felisberto-Rodrigues, Jemima C Thomas, Craig McAndrew, et al.
Cancer Research|October 30, 2003
Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profilingPaul A Clarke, Mark L George, Sandra Easdale, et al.
Molecular Cancer Therapeutics|October 22, 2016
The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma CellsTeresa Delgado-Goni, Maria Falck Miniotis, Slawomir Wantuch, et al.
Cancer Journal (Sudbury, Mass.)|October 15, 2009
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug developmentDaniel S W Tan, George V Thomas, Michelle D Garrett, et al.
Journal of Biomolecular Screening|December 20, 2005
Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screenYvette Newbatt, Samantha Burns, Robert Hayward, et al.
Pageof 32